CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost immune system against stomach and esophageal cancers
Disease control TerminatedThis study is testing whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can better treat certain cancers of the esophagus and stomach junction. It involves patients who are scheduled for surgery. The goal is to see if this co…
Matched conditions: CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Radiation blitz tested to control spreading stomach cancer
Disease control OngoingThis study is for people with advanced stomach or esophageal cancer that has spread to only a few other places in the body. It tests if adding a short course of targeted radiation to standard chemotherapy works better than chemotherapy alone to control the cancer and help patient…
Matched conditions: CLINICAL STAGE IVA ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC